Special Issue

Early Diagnosis and Targeted Therapy of Pancreatic Cancer

Message from the Guest Editor

Steady progress has been made in understanding the biology of pancreatic cancer, yet further improvement in the treatment and early diagnosis of pancreatic cancer is still required to address unmet needs. Cytotoxic chemotherapy of pancreatic carcinoma has remained a mainstay of treatment though with modest benefit, and targeted- and immuno-therapies have been focuses of intensive investigation. The application of stereotactic body radiation, radiosensitizers, and MRI-guided radiation therapy have shown the good potential of improving the therapeutic response of pancreatic cancer. New technologies involving tumor molecular profiling and blood-based biopsy for circulating tumor cells/DNA and extracellular vesicles have demonstrated strong potential for the early detection and diagnosis of pancreatic cancer. Machine and deep learning for analytics of big data have emerged as powerful predictive tools in pancreatic cancer. The aims of this Special Issue are to generate a collection of articles that focus on recent advances of diagnosis and treatment in pancreatic cancer, with the goal of advancing our understanding of and treatments for this challenging oncological disease.

Guest Editor

Dr. Nelson Yee

Penn State Cancer Institute, 500 University Drive, Hershey, PA 17033-0850, USA

Deadline for manuscript submissions

closed (30 September 2024)

Biomedicines

an Open Access Journal by MDPI

**Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed**

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).